Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future new fundraising through debt or equity in the transcript. The company recently completed a significant QIP (Qualified Institutional Placement) of INR 350 crores, which strengthened their balance sheet and provided capital to support expansion. No specific plans or guidance regarding raising new debt or equity were discussed or indicated during the call. The focus remains on improving store-level profitability and moderate store expansion, supported by existing capital resources. Overall, the discussion highlights confidence in growth withou

Any current/future capex/capital investment/strategic investment?

The increase in inventory levels and capex amounting to around INR 114 crores for the year is primarily in anticipation of upcoming store openings. The company plans to open between 500 to 700 new stores in FY27, with 80%-90% being COCO stores, necessitating capex for store setup. Intangible Assets Under Development (approx. INR 14 crores) represent pre-operative expenses like drug licenses and regulatory approvals related to stores under development, indicating ongoing store expansion investments. Marketing spend, which supports brand visibility and growth, has increased proportionally

Future growth expectations in sales/revenue/volumes?

FY27 expansion planned to open 500-700 new stores, mostly COCO format (80%-90%). Moderate store addition pace in Q2 and Q3 to focus on improving store-level profitability. Same-store sales growth (SSG) remains strong at ~25%-30%, even without new stores. New stores (~800 opened in FY26) are expected to deliver ~100% growth in their second year. Continuing store additions in Q1, with ramp-up planned again in Q3 and Q4. Confident of sustaining robust growth trajectory if execution on store additions and SSG continues. Mature stores show healthy SSG of ~20%-24% annually. Target to expand the Dava

Future growth expectations in earnings/operating earnings/profits/EPS?

Zota Healthcare is confident about sustaining a robust growth trajectory driven by both store additions and same-store sales growth. FY27 plans include opening 500-700 new stores, mostly COCO format, with moderated expansion pace in Q2 and Q3 to focus on improving store-level profitability. Same-store sales growth remains strong at 25%-30%, even without new store additions, signaling substantial organic growth potential. Newer stores (~800 opened in FY26) are expected to deliver close to 100% growth in their second year, further fueling revenue. EBITDA turned positive in FY26 with margin impro

Current/ Expected Orderbook/ Pending Orders?

As of the recent quarter, Zota Healthcare had around 400–600 stores under process (pipeline) for opening. In the previous quarter, approximately 218 stores were launched. Around 230–240 stores were already opened from the pipeline in the prior quarter. For the current quarter, the company expects to open roughly 200+ additional stores from the remaining pipeline. For the financial year FY27, Zota Healthcare plans to open between 500 to 700 stores overall. Store additions will be moderated in the next 1-2 quarters with a focus on improving store-level profitability before ramping up again in Q3

IN US

Sale is live|00:00:00left today

Zota Health Care LtdQ1 FY26Pharmaceuticals & Biotechnology

Zota Health Care Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,390Market Cap: ₹4.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→FY27 expansion planned to open 500-700 new stores, mostly COCO format (80%-90%).
→Moderate store addition pace in Q2 and Q3 to focus on improving store-level profitability.
→Same-store sales growth (SSG) remains strong at ~25%-30%, even without new stores.
→New stores (~800 opened in FY26) are expected to deliver ~100% growth in their second year.
→Continuing store additions in Q1, with ramp-up planned again in Q3 and Q4.
→Confident of sustaining robust growth trajectory if execution on store additions and SSG continues.
→Mature stores show healthy SSG of ~20%-24% annually.
→Target to expand the Davaindia network to 5,000+ stores by FY29.
→Revenue growth driven by scale benefits, integrated model, and private label portfolio.

Margin guidance

Category 3

→Zota Healthcare is confident about sustaining a robust growth trajectory driven by both store additions and same-store sales growth.
→FY27 plans include opening 500-700 new stores, mostly COCO format, with moderated expansion pace in Q2 and Q3 to focus on improving store-level profitability.
→Same-store sales growth remains strong at 25%-30%, even without new store additions, signaling substantial organic growth potential.
→Newer stores (~800 opened in FY26) are expected to deliver close to 100% growth in their second year, further fueling revenue.
→EBITDA turned positive in FY26 with margin improvement to 4.82%; operational leverage is expected to strengthen with scale.
→Margins, especially gross margins in COCO stores, are sustainable and improving, supporting profitability expansion.
→Overall, consistent margin expansion, strong sales growth, and operational efficiencies point toward significant improvement in earnings and profits moving forward, although the company does not provide explicit numerical guidance.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or future new fundraising through debt or equity in the transcript.
→The company recently completed a significant QIP (Qualified Institutional Placement) of INR 350 crores, which strengthened their balance sheet and provided capital to support expansion.
→No specific plans or guidance regarding raising new debt or equity were discussed or indicated during the call.
→The focus remains on improving store-level profitability and moderate store expansion, supported by existing capital resources.
→Overall, the discussion highlights confidence in growth without indicating immediate need for additional fundraising.

Order book

Yes

→As of the recent quarter, Zota Healthcare had around 400–600 stores under process (pipeline) for opening.
→In the previous quarter, approximately 218 stores were launched.
→Around 230–240 stores were already opened from the pipeline in the prior quarter.
→For the current quarter, the company expects to open roughly 200+ additional stores from the remaining pipeline.
→For the financial year FY27, Zota Healthcare plans to open between 500 to 700 stores overall.
→Store additions will be moderated in the next 1-2 quarters with a focus on improving store-level profitability before ramping up again in Q3 and Q4.
→Around 80% to 90% of these new stores will be COCO format, with 100–150 planned as FOFO stores.

Capex plans

Yes

→The increase in inventory levels and capex amounting to around INR 114 crores for the year is primarily in anticipation of upcoming store openings.
→The company plans to open between 500 to 700 new stores in FY27, with 80%-90% being COCO stores, necessitating capex for store setup.
→Intangible Assets Under Development (approx. INR 14 crores) represent pre-operative expenses like drug licenses and regulatory approvals related to stores under development, indicating ongoing store expansion investments.
→Marketing spend, which supports brand visibility and growth, has increased proportionally with sales but remains rational and controlled.
→Overall, capex is focused on scaling store network and building a strong foundation for future growth and accessibility in affordable healthcare.

How does Zota Health Care Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Zota Health Care Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Zota Health Care Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio